tradingkey.logo

HeartSciences Inc

HSCS
查看详细走势图
2.990USD
+0.180+6.32%
收盘 02/06, 16:00美东报价延迟15分钟
9.18M总市值
亏损市盈率 TTM

HeartSciences Inc

2.990
+0.180+6.32%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+6.32%

5天

-7.43%

1月

-10.75%

6月

-16.71%

今年开始到现在

-3.24%

1年

-21.36%

查看详细走势图

TradingKey HeartSciences Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

HeartSciences Inc当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名131/205位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价10.60。中期看,股价处于平稳状态。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

HeartSciences Inc评分

相关信息

行业排名
131 / 205
全市场排名
378 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

HeartSciences Inc亮点

亮点风险
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
业绩增长期
公司处于发展阶段,最新年度总收入4.35K美元
利润高增长
公司净利润处于行业前列,最新年度总收入4.35K美元
估值低估
公司最新PE估值-0.46,处于3年历史低位
机构加仓
最新机构持股181.19K股,环比增加30.01%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值18.56K

分析师目标

根据 2 位分析师
买入
评级
10.600
目标均价
+261.77%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

HeartSciences Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

HeartSciences Inc简介

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
公司代码HSCS
公司HeartSciences Inc
CEOSimpson (Andrew)
网址https://heartsciences.com/
KeyAI